New target DDR1: A "double-edged sword" in solid tumors.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer remains a significant global health threat, necessitating novel therapeutic strategies.
• Identifying new molecular targets is crucial for advancing cancer treatment.
• Discoidin domain receptor 1 (DDR1) has emerged as a promising, yet complex, target in oncology.

Purpose of the Study:

• To provide a comprehensive review of DDR1's role in human solid tumors.
• To explore DDR1's structure, normal function, and expression patterns.
• To elucidate DDR1's dual role as a potential facilitator and inhibitor in cancer progression.

Main Methods:

• Literature review of existing research on DDR1 in cancer.
• Analysis of DDR1 expression patterns in single cells.
• Synthesis of data on DDR1's involvement in cancer mechanisms and prognosis.
• Overview of current DDR1-targeting drug and antibody development.

Main Results:

• DDR1 exhibits complex functions, acting as a "double-edged sword" in various solid tumors.
• Abnormal DDR1 expression is linked to cancer occurrence and influences patient prognosis.
• Current research highlights DDR1's potential as a therapeutic target.

Conclusions:

• DDR1's multifaceted role in cancer warrants further investigation.
• Targeting DDR1 presents a promising avenue for future solid tumor treatments.
• Continued research and development of DDR1-specific therapies are essential for clinical progress.